Huge Viagra market envisaged in Malaysia
The potential sales figures in Malaysia for the erectile dysfunctiondrug Viagra (sildenafil) were described by its developer, Pfizer, as "mind-boggling." If each of the 500,000 men estimated to be wanting to take Viagra uses an average of four tablets a month, sales could come close to 1 billion ringgit ($263 million) a year, noted Pfizer Malaysia managing director Radzmi Rahmat. About 1.2 million Malaysians are believed to be suffering erectile dysfunction, according to Bloomberg News.
Just prior to the launch of Viagra in Malaysia, Deputy Health Minister Mohd Ali Rustan warned potential users of the risks of not taking the drug as prescribed or without a prescription. He also urged the wives of Viagra users to ensure their husbands abided by the prescribed dosage, according to the Malaysian Bernama news agency.
Viagra will be sold in Malaysia for 28 ringgit per 25mg tablet, according to Pfizer, while the 50mg and 100mg tablets will sell for 38 ringgit and 48 ringgit respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze